Navigation Links
FASEB Welcomes New President, William T. Talman, M.D.
Date:7/1/2010

BETHESDA, Md., July 1 /PRNewswire-USNewswire/ -- William T. Talman, M.D., assumed office as the 95th President of the Federation of American Societies for Experimental Biology (FASEB) on July 1, 2010. Talman is a Professor of Neurology and Neuroscience at the University of Iowa and is a practicing physician at the University Hospital and at the Iowa City Veterans Affairs (VA) hospital where he is the Chief of the Neurology Service. He will serve for one year as the leader of FASEB, a coalition of 23 member societies comprising more than 100,000 scientists and engineers.

"The opportunities for continued progress have never been greater, but those opportunities depend on adequate resources," Talman stated. "In 2009, supplemental appropriations from the American Recovery and Reinvestment Act (ARRA) restored purchasing power at the National Institutes of Health (NIH) and provided a timely investment in biomedical research across the nation. However, if we return to pre-ARRA funding levels in fiscal year 2011, we will have to curtail many promising research studies." As President, Talman will lead FASEB's advocacy efforts to encourage Congress and the Obama Administration to achieve the goal of sustainable funding for research.

A graduate of the University of Virginia School of Medicine, Talman's research focuses on the brain's control of the cardiovascular system, and his clinical specialty is autonomic dysfunction, for which he has been recognized by Best Doctors in America for the past eight years. Dr. Talman is the Past President of the International Society for Autonomic Neuroscience and past chair of the Public Affairs Committee of the American Physiological Society. He is also Associate Editor for Cellular and Molecular Neurobiology and has served as a reviewer for NIH Study Sections, VA Merit Review Boards, the National Science Foundation, and the American Heart Association.

Joseph C. LaManna, Ph.D., is FASEB's President-Elect and Fred D. Finkelman, M.D., the new Treasurer of the Federation. Dr. LaManna is a Professor of Physiology and Biophysics, Neurology and Neuroscience at the Case Western Reserve University School of Medicine and he has been involved as a cerebrovascular researcher for more than 30 years. Dr. Finkelman received his M.D. from Yale University and is a Professor of Medicine and Professor of Pediatrics at the University of Cincinnati College of Medicine.

FASEB is composed of 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve — through their research — the health, well-being, and productivity of all people. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.


'/>"/>
SOURCE Federation of American Societies for Experimental Biology
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FASEB Announces Recipient of the 2011 Excellence in Science Award
2. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
3. FASEB Encourages NIGMS to Broaden Scientific Training Opportunities
4. Laureate Pharma Welcomes Three New Members to Business Development Team
5. Sundia Welcomes Professional U.S. Delegation
6. NovaMin Technology Inc. Welcomes New Board Member
7. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
8. Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S.
9. UCLA welcomes startup to new incubator space at California NanoSystems Institute
10. Boston Scientific Welcomes Launch of Syntax Score Website
11. Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... Corp. ("Zenith" or the "Company") announces webcast details for a ... and Special Meeting. The Zenith Annual and ... 15, 2016 at Mount Royal University, ... Gate SW, Calgary, Alberta , commencing at ... circular, containing the matters to be considered at the meeting, ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
Breaking Biology News(10 mins):